|20th January 2021||Kevin Lee||351||Open or private sale||$33.00||$11,583.00|
|20th January 2021||Kevin Lee||100||Open or private sale||$32.02||$3,202.00|
|20th January 2021||Kevin Lee||734||Open or private sale||$31.33||$22,994.16|
|19th January 2021||Kevin Lee||371||Open or private sale||$30.22||$11,211.36|
|19th January 2021||Kevin Lee||100||Open or private sale||$31.09||$3,109.00|
|19th January 2021||Kevin Lee||4,529||Open or private sale||$29.14||$131,970.08|
|15th January 2021||Kevin Lee||5,000||Open or private sale||$27.01||$135,050.00|
|14th January 2021||Lee Kalowski||10,000||Open or private sale||$25.00||$250,000.00|
|14th January 2021||Lee Kalowski||10,000||Exercise of derivative||$1.60||$16,000.00|
|14th January 2021||Kevin Lee||5,000||Open or private sale||$25.00||$125,000.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Bicycle Therapeutics Plc engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display platform to identify bicycles.